A rare cutaneous infection with <i>Mycobacterium chelonae</i> in a pediatric patient treated with trametinib for <i>KRAS</i>‐mutated diffuse glioma-Reference-Cited by-同舟云学术

A rare cutaneous infection with Mycobacterium chelonae in a pediatric patient treated with trametinib for KRAS‐mutated diffuse glioma

Published:2024-08-15 Issue: Volume: Page:
ISSN:0736-8046
Container-title:Pediatric Dermatology
language:en
Short-container-title:Pediatric Dermatology

Author:

Ryan Chenin¹^ORCID,Moore Angel¹,Davis Matthew²,Yazel Caitlin²,Momtahen Shabnam¹³,Ricci Angela M.⁴,Talbot Elizabeth A.¹⁵,Mann Julianne⁶^ORCID,Pace Nicole⁶

Affiliation:

1. Geisel School of Medicine at Dartmouth Hanover New Hampshire USA

2. Department of Dermatology Dartmouth Hitchcock Medical Center Lebanon New Hampshire USA

3. Department of Pathology and Laboratory Medicine Dartmouth‐Hitchcock Medical Center Lebanon New Hampshire USA

4. Section of Pediatric Hematology/Oncology, Department of Pediatrics Children's Hospital at Dartmouth‐Hitchcock Lebanon New Hampshire USA

5. Infectious Disease and International Health Dartmouth‐Hitchcock Medical Center Lebanon New Hampshire USA

6. Section of Dermatology, Department of Surgery Dartmouth‐Hitchcock Medical Center Lebanon New Hampshire USA

Abstract

AbstractMitogen‐activated extracellular signal‐regulated kinase inhibitors (MEKi) represent a promising new therapy for pediatric patients with low‐grade gliomas, which frequently have abnormal signaling within the mitogen‐activated protein kinase (MAP kinase) pathway. However, understanding of long‐term efficacy and toxicity is limited in pediatric glioma patients. This article describes a rare presentation of a widespread cutaneous infection with Mycobacterium chelonae in a pediatric patient with a low‐grade glioma treated with trametinib.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/pde.15718

Reference15 articles.

1. Response to trametinib treatment in progressive pediatric low-grade glioma patients

2. A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study

3. Phase 1 trial of trametinib alone and in combination with dabrafenib in children and adolescents with relapsed solid tumors or neurofibromatosis type 1 (NF1) progressive plexiform neurofibromas (PN).

4. Mycobacterium chelonae